- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cancer Treatment Speeded by Genome Superhighway: Creator
A new supercomputer-based network will allow doctors to use genomic sequencing to speed cancer treatment and could increase survival chances for patients, its creator, billionaire healthcare businessman Dr. Patrick Soon Shiong, said on Tuesday.
A group of technology and healthcare companies have formed the superhighway that will accelerate the time for genetic analysis of a patient's tumor to 47 seconds from eight to 10 weeks now, Soon-Shiong said in a press release.
The idea of matching a cancer to the most effective treatment, by determining the tumor's DNA profile, has been a dream for more than a decade. Some experts remain skeptical, however, that faster information will save lives.
Read the full story: http://reut.rs/QGPppR
Source: Reuters
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL
December 17th 2024Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL
December 10th 2024Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
Read More
